Pharmafile Logo
Pharmafocus logo
Advanced Search

ixazomib

Showing 7 posts of 7 posts found.

Ninlaro

Takeda in myeloma research drive

January 14, 2016
Medical Communications, Research and Development Ninlaro, Phase II, Takeda, Takeda oncology, eric low, ixazomib, multiple myeloma, myeloma

Takeda is funding the research charity Myeloma UK to run a Phase II study of its multiple myeloma treatment Ninlaro, …

News
Ninlaro

Takeda’s Ninlaro extends myeloma survival in trial

December 7, 2015
Manufacturing and Production, Research and Development Ninlaro, Takeda, ash, ixazomib, multiple myeloma

Takeda has presented trial data showing that treatment with its oral proteasome inhibitor Ninlaro extended progression free survival by 35% …

News
Clinigen logo

Clinigen launches UK managed access program for Takeda’s ixazomib

November 30, 2015
Sales and Marketing Clinigen, Takeda, ixazomib, managed access, multiple myeloma, oncology

Clinigen and Takeda have struck a deal to allow patients in the UK to access the multiple myeloma drug ixazomib …

News
Takeda oncology

Takeda in Velcade patent blow

August 25, 2015
Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib

Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …

News

Takeda gets European MAA approval for ixazomib

August 21, 2015
Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma

Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …

News
Takeda oncology

Takeda cancer drug gets EMA boost

July 29, 2015
Research and Development, Sales and Marketing Takeda, ixazomib, multiple myeloma

The EMA has granted Takeda an accelerated assessment for its multiple myeloma drug, ixazomib. The Agency’s Committee for Medicinal Products …

News

Future bleak for Novartis’ myeloma drug

November 21, 2014
Medical Communications FDA, Farydak, Novartis, ixazomib, myeloma, panobinostat

Novartis suffered a major disappointment with the negative FDA panel vote for multiple myeloma candidate Farydak earlier this month, but …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024